

Bergamottin Induces DNA Damage and Inhibits Malignant Progression in Melanoma by Modulating miR-145/Cyclin D1 Axis [Retraction]

Zhao Z, Liao N. *Onco Targets Ther.* 2021;14:3769–3781. <https://doi.org/10.2147/OTT.S275322>

We, the Editors and Publisher of the journal *OncoTargets and Therapy*, have retracted the published article.

After publication, concerns have been raised by a third party in 2026 about the integrity of the data in Figures 2, 5, 6, and 7 of the article.

Further investigation conducted by the Journal and Publisher confirmed the following:

- Unexpected similarities between the cell staining images in Figure 2 that are representative of different samples and treatment conditions
- Unexpected similarities between the flow cytometry plots in Figures 3B and 6F that are representative of different samples and treatment conditions
- Unexpected similarities between the Western blots in Figures 5G and 6B that are representative of different samples and treatment conditions
- Unexpected similarities between the immunohistochemistry staining images in Figure 7 that are representative of different samples and treatment conditions

When informed that concerns had been raised, the authors checked their data and confirmed there are fundamental errors present. The authors have requested the retraction of this article and apologise for the errors.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>